Picture of Lifecore Biomedical logo

LFCR Lifecore Biomedical Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Lifecore Biomedical, fiscal year end - May 25th, USD millions except per share, conversion factor applied.

R2021
May 30th
R2022
May 29th
2023
May 28th
2024
May 26th
2025
May 25th
Period Length:52 W52 W52 W52 W52 W
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue101111103128129
Cost of Revenue
Gross Profit38.939.12841.940.3
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses111123149137146
Operating Profit-9.93-11.8-45.5-8.84-17.2
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-29.8-20.7-63.99.51-38.7
Provision for Income Taxes
Net Income After Taxes-23.4-15.5-64.29.33-38.7
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-32.3-117-99.612-38.7
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-32.3-117-99.612-44.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.1191.55-1.220.606-1.18